comparemela.com

Latest Breaking News On - Exploratory outcomes - Page 1 : comparemela.com

Pamrevlumab for Idiopathic Pulmonary Fibrosis

This randomized clinical trial compares the efficacy and safety of pamrevlumab vs placebo for patients with idiopathic pulmonary fibrosis.

United statesSan diegoEteläuomen läiUniversity of california san diegoSouth koreaRoche genentechEisai pharmaShionogi pharmaGanesh raghuAstellas pharmaTaiho pharmaKey researchInternational conference on harmonisationNational research foundation of koreaBristol myers squibbTechnology of china

Biogen Inc : New Data at ECTRIMS 2021 Highlight Biogen s Focus on Patient-Centered Outcomes and Improving the MS Patient Experience

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower

United statesUnited kingdomJohn foleyMaha radhakrishnanCharles weissmannWalter gilbertHeinz schallerZhovtis ryersonAshleigh kossRobert naismithMike henckeKenneth murrayAmerican academy of neurology virtual annual meetingProgram databaseWashington university school of medicineExchange commission

vimarsana © 2020. All Rights Reserved.